6533b7d1fe1ef96bd125c256
RESEARCH PRODUCT
Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells
Michael HeikeWolfgang HerrThomas WlfelKarl-hermann Meyer Zum BschenfeldeAlexander Knuthsubject
Cytotoxicity ImmunologicCancer ResearchCellular immunitymedicine.medical_treatmentImmunologyActive immunizationLeukocyte CountImmune systemTumor Cells CulturedmedicineHumansImmunology and AllergyCytotoxic T cellAmelanotic melanomaMelanomaCells Culturedbusiness.industryVaccinationReproducibility of ResultsImmunotherapyT lymphocytemedicine.diseaseCTL*OncologyImmunologyImmunotherapyLymphocyte Culture Test MixedbusinessT-Lymphocytes Cytotoxicdescription
A limiting-dilution assay was developed and used to determine the frequency of autologous tumor-reactive cytotoxic T lymphocytes (CTL) in peripheral blood of a melanoma patient MZ2, who has been free of detectable disease since several years. In this patient, the frequencies of tumor-reactive CTL spontaneously varied only by a factor of 1.5. After vaccinations with autologous mutagenized and lethally irradiated tumor cells a two- to tenfold increase in frequencies of tumor-reactive CTL was found within the first 2 weeks. Thereafter, CTL frequencies returned to values measured prior to vaccinations. We conclude, that the limiting-dilution assay applied in this study can detect changes in the T cell response to autologous tumor cells. The frequency of tumor-reactive CTL determined with this approach can serve as an immunological parameter for monitoring the T cell response to autologous tumor cells in individual cancer patients receiving tumor cell vaccinations.
year | journal | country | edition | language |
---|---|---|---|---|
1994-08-01 | Cancer Immunology Immunotherapy |